Market News

Foundation Medicine, Inc. (FMI) EPS Estimated At $-1.00; Davita Healthcare Partners (DVA) Sentiment Is 0.89

Analysts expect Foundation Medicine, Inc. (NASDAQ:FMI) to report $-1.00 EPS on February, 28.They anticipate $0.02 EPS change or 1.96% from last quarter’s $-1.02 EPS. After having $-0.90 EPS previously, Foundation Medicine, Inc.’s analysts see 11.11% EPS growth. The stock increased 5.11% or $3.35 during the last trading session, reaching $68.95. About 285,328 shares traded. Foundation Medicine, Inc. (NASDAQ:FMI) has risen 124.70% since February 16, 2017 and is uptrending. It has outperformed by 108.00% the S&P500.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease . The company has market cap of $13.54 billion. It operates through two divisions, DaVita Kidney Care and DaVita Medical Group. It has a 27.78 P/E ratio. The firm operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.

Ratings analysis reveals 25% of DaVita’s analysts are positive. Out of 4 Wall Street analysts rating DaVita, 1 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. DVA was included in 4 notes of analysts from September 6, 2016. The rating was downgraded by Bank of America on Tuesday, September 6 to “Neutral”. The company was upgraded on Tuesday, September 20 by Raymond James. The stock of DaVita Inc. (NYSE:DVA) earned “Neutral” rating by Citigroup on Tuesday, September 6. Robert W. Baird downgraded the stock to “Neutral” rating in Tuesday, December 13 report.

Since January 1, 0001, it had 0 buys, and 6 sales for $8.31 million activity.

The stock decreased 1.22% or $0.91 during the last trading session, reaching $73.84. About 1.84 million shares traded or 0.76% up from the average. DaVita Inc. (DVA) has declined 16.51% since February 16, 2017 and is downtrending. It has underperformed by 33.21% the S&P500.

Consulta Ltd holds 7.15% of its portfolio in DaVita Inc. for 900,000 shares. Park West Asset Management Llc owns 1.97 million shares or 6.99% of their US portfolio. Moreover, Endurant Capital Management Lp has 4.93% invested in the company for 274,223 shares. The New York-based Gates Capital Management Inc. has invested 4.05% in the stock. Speece Thorson Capital Group Inc, a Minnesota-based fund reported 321,182 shares.

Among 11 analysts covering Foundation Medicine (NASDAQ:FMI), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Foundation Medicine had 14 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, March 7 by Janney Capital. The stock of Foundation Medicine, Inc. (NASDAQ:FMI) earned “Buy” rating by BTIG Research on Monday, May 15. The firm has “Market Perform” rating given on Wednesday, September 16 by Wells Fargo. BTIG Research initiated it with “Buy” rating and $30 target in Monday, September 14 report. The company was downgraded on Thursday, November 3 by Benchmark. BTIG Research downgraded Foundation Medicine, Inc. (NASDAQ:FMI) on Wednesday, November 4 to “Neutral” rating. As per Thursday, July 30, the company rating was downgraded by JMP Securities. The firm has “Buy” rating by Cowen & Co given on Thursday, February 15. UBS maintained the shares of FMI in report on Wednesday, September 21 with “Neutral” rating.

Leave a Reply

Your email address will not be published. Required fields are marked *